ParenteralDosed ingredient Cosmetic cross-reference

Indigotindisulfonate Sodium

CAS 860-22-0

Indigotindisulfonate Sodium (CAS 860-22-0) is a Phase 4 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Indigotindisulfonate Sodium
CAS Number
860-22-0
UNII
D3741U8K7L
InChIKey
KHLVKKOJDHCJMG-QDBORUFSSA-L
ChEMBL ID
CHEMBL2105023
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL2105023 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 27043.164516129033 nM 31 -
- Potency 48015.08235294118 nM 16 -
- IC50 2833.3333333333335 nM 3 -
- Ki 42100 nM 1 -
- Potency 19952.6 nM 1 -
SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
INDIGOTINDISULFONATE SODIUM 227312 SU MTHSPL
Indigotindisulfonate Sodium 227312 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Indigotindisulfonate Sodium used for in pharmaceutical contexts?

Indigotindisulfonate Sodium (CAS 860-22-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Indigotindisulfonate Sodium?

No adverse-event association or SIDER side-effect rows are rendered for Indigotindisulfonate Sodium in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Indigotindisulfonate Sodium also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for CI 73015 with EU status "permitted".

What clinical phase is Indigotindisulfonate Sodium in?

Indigotindisulfonate Sodium is rendered with ChEMBL max phase 4 (approved).